title: Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures.
abstract: Platelet-derived growth factor (PDGF) has been shown to be essential in the activation of hepatic stellate cells (HSCs), contributing to the onset and development of hepatic fibrosis. Recently, sphingosine-1-phosphate (S1P) has been shown to be a mitogen and stimulator of chemotaxis also for HSCs. Since it has been demonstrated in several cell types that cross-talk between PDGF and S1P signalling pathways occurs, our aim was to investigate the potential antifibrotic effect of FTY720, whose phosphorylated form acts as a potent S1P receptor (S1PR) modulator, on HSCs. FTY720 inhibits cell proliferation and migration after PDGF stimulation on HSCs in a concentration range between 0.1 and 1 muM. By using compounds that block S1P signalling (PTX and VPC23019), we assessed that FTY720 also acts in an S1P receptor-independent way by decreasing the level of tyrosine phosphorylation of PDGF receptor, with subsequent inhibition of the PDGF signalling pathway. In addition, inhibition of sphingosine kinase2 (SphK2), which is responsible for FTY720 phosphorylation, by DMS/siRNA unveils a mechanism of action irrespective of its phosphorylation, in particular decreasing the level of S1P(1) on the plasma membrane. These findings led us to hypothesize a potential use of FTY720 as a potential antifibrotic drug for further clinical application.
authors.affiliation: Department of Biochemistry, University of Padova, Viale G. Colombo 3, 35121 Padova, Italy.
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Brunati
authors.forename: Elena
authors.initials: E
authors.lastname: Tibaldi
authors.forename: Amedeo
authors.initials: A
authors.lastname: Carraro
authors.forename: Enrico
authors.initials: E
authors.lastname: Gringeri
authors.forename: Francesco
authors.initials: F
authors.lastname: D'Amico
authors.forename: Antonio
authors.initials: A
authors.lastname: Toninello
authors.forename: Maria Lina
authors.initials: ML
authors.lastname: Massimino
authors.forename: Mario Angelo
authors.initials: MA
authors.lastname: Pagano
authors.forename: Giovanna
authors.initials: G
authors.lastname: Nalesso
authors.forename: Umberto
authors.initials: U
authors.lastname: Cillo
mesh_terms: D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D000068876:Fingolimod Hydrochloride; D007155:Immunologic Factors / Q000494:pharmacology; D008099:Liver / Q000187:drug effects; D008103:Liver Cirrhosis / Q000517:prevention & control*; D008246:Lysophospholipids / Q000378:metabolism / Q000502:physiology*; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D011409:Propylene Glycols / Q000494:pharmacology*; D021381:Protein Transport / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D020239:Receptor Cross-Talk / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology
chemical_list: D007155:Immunologic Factors; D008246:Lysophospholipids; D010982:Platelet-Derived Growth Factor; D011409:Propylene Glycols; C060506:sphingosine 1-phosphate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine